PI3K Inhibition for Squamous Cell Head and Neck Carcinoma

被引：5

作者：

Desilets, Antoine ^{[1
,2
]}

Soulieres, Denis ^{[1
]}

机构：

[1] Ctr Hosp Univ Montreal CHUM, Pavillon C,1000 Rue St Denis, Montreal, PQ H2X 0C1, Canada

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER JOURNAL | 2022年 / 28卷 / 05期

关键词：

Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy; PHOSPHOINOSITIDE 3-KINASE INHIBITOR; I DOSE-ESCALATION; BUPARLISIB BKM120; PACLITAXEL; RECURRENT; CHEMOTHERAPY; COMBINATION; EXPRESSION; RECEPTOR; NIVOLUMAB;

D O I：

10.1097/PPO.0000000000000618

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.

引用

页码：369 / 376

页数：8

共 50 条

[41] PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma
Libo Wang
Kejun Chen
Siyuan Weng
Hui Xu
Yuqing Ren
Quan Cheng
Peng Luo
Jian Zhang
Zaoqu Liu
Xinwei Han
World Journal of Surgical Oncology, 21
[42] NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in head and neck squamous cell carcinoma
Johnson, Faye M.
Sambandam, Vaishnavi
Shen, Li
Zhang, Ming
Saigal, Rishi
Tong, Pan
Mazumdar, Tuhina
Byers, Lauren A.
Pickering, Curtis
Myers, Jeffrey N.
Wang, Jing
Frederick, Mitchell
CANCER RESEARCH, 2016, 76
[43] Dual PI3K/mTOR blockade by NVP-BEZ235 sensitizes head and neck squamous cell carcinoma to radiotherapy
Gao, Ming
Wang, Chun-Wei
Fang, Chun Sheng
Lu, Yen-Shen
Cheng, Ann-Lii
CANCER RESEARCH, 2012, 72
[44] Overexpressed HGF promotes metastasis of squamous cell carcinoma of the head and neck through the PI3K/Akt and JNK signaling pathways
Guo, Nan
Liang, Jiwang
Gao, Xin
Yang, Xiao
Fan, Xinlong
Zhao, Yuejiao
FUTURE ONCOLOGY, 2021, 17 (33) : 4527 - 4543
[45] New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors
De Felice, Francesca
Urbano, Teresa Guerrero
ORAL ONCOLOGY, 2017, 67 : 119 - 123
[46] Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
Su, Yu-Chieh
Lee, Wei-Chang
Wang, Chih-Chun
Yeh, Shyh-An
Chen, Wen-Hui
Chen, Po-Jen
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
[47] AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Elkabets, Moshe
Pazarentzos, Evangelos
Juric, Dejan
Sheng, Qing
Pelossof, Raphael A.
Brook, Samuel
Benzaken, Ana Oaknin
Rodon, Jordi
Morse, Natasha
Yan, Jenny Jiacheng
Liu, Manway
Das, Rita
Chen, Yan
Tam, Angela
Wang, Huiqin
Liang, Jinsheng
Gurski, Joseph M.
Kerr, Darcy A.
Rosell, Rafael
Teixido, Cristina
Huang, Alan
Ghossein, Ronald A.
Rosen, Neal
Bivona, Trever G.
Scaltriti, Maurizio
Baselga, Jose
CANCER CELL, 2015, 27 (04) : 533 - 546
[48] The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells
Glorieux, Mary
Dok, Ruveyda
Nuyts, Sandra
SCIENTIFIC REPORTS, 2020, 10 (01)
[49] The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells
Mary Glorieux
Rüveyda Dok
Sandra Nuyts
Scientific Reports, 10
[50] PDK1 drives susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition
Sambandam, Vaishnavi
Shen, Li
Peng, Shaohua
Mazumdar, Tuhina
Pickering, Curtis
Myers, Jeffrey
Wang, Jing
Frederick, Mitchell
Johnson, Faye
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →